title: Amebiasis in HIV-1-infected Japanese men: clinical features and response to therapy.
abstract: Invasive amebic diseases caused by Entamoeba histolytica are increasing among men who have sex with men and co-infection of ameba and HIV-1 is an emerging problem in developed East Asian countries. To characterize the clinical and epidemiological features of invasive amebiasis in HIV-1 patients, the medical records of 170 co-infected cases were analyzed retrospectively, and E. histolytica genotype was assayed in 14 cases. In this series of HIV-1-infected patients, clinical presentation of invasive amebiasis was similar to that described in the normal host. High fever, leukocytosis and high CRP were associated with extraluminal amebic diseases. Two cases died from amebic colitis (resulting in intestinal perforation in one and gastrointestinal bleeding in one), and three cases died from causes unrelated to amebiasis. Treatment with metronidazole or tinidazole was successful in the other 165 cases. Luminal treatment was provided to 83 patients following metronidazole or tinidazole treatment. However, amebiasis recurred in 6 of these, a frequency similar to that seen in patients who did not receive luminal treatment. Recurrence was more frequent in HCV-antibody positive individuals and those who acquired syphilis during the follow-up period. Various genotypes of E. histolytica were identified in 14 patients but there was no correlation between genotype and clinical features. The outcome of metronidazole and tinidazole treatment of uncomplicated amebiasis was excellent even in HIV-1-infected individuals. Luminal treatment following metronidazole or tinidazole treatment does not reduce recurrence of amebiasis in high risk populations probably due to amebic re-infection.
authors.affiliation: AIDS Clinical Center, National Center for Global Health and Medicine, Tokyo, Japan.
authors.forename: Koji
authors.initials: K
authors.lastname: Watanabe
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Gatanaga
authors.forename: Aleyla
authors.initials: A
authors.lastname: Escueta-de Cadiz
authors.forename: Junko
authors.initials: J
authors.lastname: Tanuma
authors.forename: Tomoyoshi
authors.initials: T
authors.lastname: Nozaki
authors.forename: Shinichi
authors.initials: S
authors.lastname: Oka
mesh_terms: D000328:Adult; D000562:Amebiasis / Q000188:drug therapy / Q000453:epidemiology / Q000235:genetics / Q000821:virology*; D000563:Amebicides / Q000008:administration & dosage / Q000627:therapeutic use; D004748:Entamoeba histolytica / Q000302:isolation & purification*; D015658:HIV Infections / Q000453:epidemiology / Q000469:parasitology*; D015497:HIV-1 / Q000302:isolation & purification*; D006526:Hepatitis C / Q000453:epidemiology / Q000821:virology; D018451:Homosexuality, Male / Q000706:statistics & numerical data; D006801:Humans; D007564:Japan / Q000453:epidemiology; D053208:Kaplan-Meier Estimate; D008297:Male; D015999:Multivariate Analysis; D012008:Recurrence; D016896:Treatment Outcome
chemical_list: D000563:Amebicides